Ocriplasmin

Drug Profile

Ocriplasmin

Alternative Names: A 01016; Jejetrea®; Jetrea; Microplasmin; Recombinant human microplasmin; Recombinant microplasmin; THR 409

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator University of Leuven
  • Developer Alcon; ThromboGenics; University of Leuven
  • Class Anti-ischaemics; Eye disorder therapies; Peptide fragments; Serine endopeptidases
  • Mechanism of Action Antiplasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal disorders; Peripheral arterial occlusive disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Marketed Retinal disorders
  • Phase II Diabetic retinopathy
  • Preclinical Retinal vein occlusion
  • Suspended Deep vein thrombosis; Peripheral arterial occlusive disorders; Stroke
  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 08 Jun 2016 Office of Biotechnology Products of the US FDA approves already diluted formulation of ocriplasmin for treatment of Retinal disorders in USA
  • 08 Jun 2016 ThromboGenics intends to launch already diluted formulation of ocriplasmin in first half of 2017 in USA
  • 01 May 2016 ThromboGenics completes the phase IV ORBIT trial in Retinal disorders (Vitreomacular adhesion/vitreomacular traction) in USA (NCT02079883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top